[go: up one dir, main page]

DE60144291D1 - Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen - Google Patents

Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen

Info

Publication number
DE60144291D1
DE60144291D1 DE60144291T DE60144291T DE60144291D1 DE 60144291 D1 DE60144291 D1 DE 60144291D1 DE 60144291 T DE60144291 T DE 60144291T DE 60144291 T DE60144291 T DE 60144291T DE 60144291 D1 DE60144291 D1 DE 60144291D1
Authority
DE
Germany
Prior art keywords
aztreonam
treatment
formulation
inhibitable
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144291T
Other languages
English (en)
Inventor
Alan Bruce Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60144291(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DE60144291D1 publication Critical patent/DE60144291D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
DE60144291T 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen Expired - Lifetime DE60144291D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
PCT/US2001/050062 WO2002051356A2 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (1)

Publication Number Publication Date
DE60144291D1 true DE60144291D1 (de) 2011-05-05

Family

ID=22980480

Family Applications (2)

Application Number Title Priority Date Filing Date
DE201112100043 Pending DE122011100043I1 (de) 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
DE60144291T Expired - Lifetime DE60144291D1 (de) 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE201112100043 Pending DE122011100043I1 (de) 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.

Country Status (19)

Country Link
US (6) US6660249B2 (de)
EP (2) EP1353647B1 (de)
JP (1) JP4646489B2 (de)
AT (1) ATE502623T1 (de)
AU (1) AU2002231244B2 (de)
BE (1) BE2011C029I2 (de)
BR (1) BRPI0116757B8 (de)
CA (2) CA2708703C (de)
CY (2) CY1111571T1 (de)
DE (2) DE122011100043I1 (de)
DK (2) DK2301524T3 (de)
ES (2) ES2406405T3 (de)
FR (1) FR11C0030I2 (de)
IL (3) IL156596A0 (de)
LU (1) LU91851I2 (de)
NL (1) NL300492I2 (de)
NO (3) NO329643B1 (de)
PT (2) PT2301524E (de)
WO (1) WO2002051356A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2301524T3 (da) * 2000-12-27 2013-07-15 Gilead Sciences Inc Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
WO2003075889A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
EP1527072A1 (de) 2002-08-05 2005-05-04 Teva Gyogyszergyar Reszvenytarsasag Herstellung von aztreonam
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
AU2004231342A1 (en) * 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
DE602004031829D1 (de) * 2003-05-20 2011-04-28 Collins Ophthalmisches arzneimittelabgabesystem
DE112004001191B4 (de) * 2003-07-02 2017-11-09 Corus Pharma Inc. Verfahren zur Herstellung des L-Lysin-Salzes von Aztreonam und Verfahren zur Bestimmung des Verunreinigungsgrads in einem amorphen Aztreonam Lysin-Salz
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
MX2007000526A (es) 2005-05-09 2007-03-28 Sicor Inc Proceso para elaborar aztreonam.
WO2008039987A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Methods of treating pulmonary distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
AR068514A1 (es) * 2007-10-01 2009-11-18 Gilead Sciences Inc Aztreonam lisina inhalada para el tratamiento de deficits de salud relacionados con la calidad de vida (cvrs) de las enfermedades pulmonares
CN107050047B (zh) 2007-11-27 2021-06-11 阿尔吉法玛公司 无菌水类或无菌油类清创组合物和包含组合制剂的产品
EP2098219A1 (de) 2008-03-05 2009-09-09 PARI Pharma GmbH Makrolidzusammensetzungen mit verbessertem Geschmack und verbesserter Stabilität
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
CN108434126B (zh) 2009-03-26 2021-11-19 普马特里克斯营业公司 治疗肺病的干粉配方与方法
PT2437783E (pt) 2009-06-03 2014-01-22 Algipharma As Tratamento de acinetobacter com oligómeros de alginato e antibióticos
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
ES2710537T3 (es) 2010-09-29 2019-04-25 Pulmatrix Operating Co Inc Polvos secos catiónicos
EP2804589A1 (de) * 2012-01-16 2014-11-26 Mahmut Bilgic Pharmazeutische formulierungen mit aztreonam
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
EP2978434A4 (de) * 2013-03-28 2016-08-17 Pharmacaribe Llc Zusammensetzungen, formulierungen und verfahren zum bioausgleich des ph-werts einer sterilen isotonischen salzlösung und von hypertonischen salzlösungen
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
EP3452152B1 (de) 2016-05-03 2025-07-02 Pneuma Respiratory, Inc. Tröpfchenabgabevorrichtung zur erzeugung und abgabe von tröpfchen an das lungensystem
KR102295739B1 (ko) 2016-05-03 2021-08-30 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
WO2017192782A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
WO2017192773A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
CA3064005C (en) 2017-05-19 2023-03-07 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
CN111093742B (zh) 2017-06-10 2022-09-16 艾诺维亚股份有限公司 用于处理流体并将流体输送到眼睛的方法和设备
US11738158B2 (en) 2017-10-04 2023-08-29 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device and methods of use
CA3079189A1 (en) 2017-10-17 2019-04-25 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法
WO2020174365A1 (en) * 2019-02-28 2020-09-03 Exorao Life Science S.R.L. Sterile aztreonam package
US12161585B2 (en) 2019-12-11 2024-12-10 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN111647537B (zh) * 2020-06-18 2022-04-26 浙江工业大学 一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
KR20240037245A (ko) 2021-06-22 2024-03-21 뉴마 레스퍼러토리 인코포레이티드 푸시 이젝션에 의한 액적 전달 장치
KR20250038748A (ko) 2022-07-18 2025-03-19 뉴마 레스퍼러토리 인코포레이티드 작은 스텝 크기 및 고해상도 에어로졸 생성 시스템 및 방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572801A (en) * 1896-12-08 Telephone-exchange
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US9126A (en) * 1852-07-13 Marcus r
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
ES2179095T3 (es) * 1994-01-14 2003-01-16 Xoma Technology Ltd Metodos y materiales anti bacterias gram positivas.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
JP4118340B2 (ja) 1996-09-04 2008-07-16 タカラバイオ株式会社 真菌抗原及びその製造方法
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
HK1043732A1 (zh) * 1998-12-17 2002-09-27 Chiron Corporation 利用烟雾状抗生素治疗严重慢性支气管炎(支气管扩张)的方法
JP2003502292A (ja) 1999-06-01 2003-01-21 バイオジェン インコーポレイテッド ヘッジホッグタンパク質のポリマー結合体及び利用
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
DK1223915T3 (da) * 1999-10-29 2006-03-06 Nektar Therapeutics Törpulverpræparater med forbedret dispersivitet
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
DK2301524T3 (da) 2000-12-27 2013-07-15 Gilead Sciences Inc Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US6841096B2 (en) * 2001-10-08 2005-01-11 California Institute Of Technology Microfabricated lenses, methods of manufacture thereof, and applications therefor
AU2002350622B2 (en) 2001-10-24 2006-09-14 Pari Pharma Gmbh Kit for the preparation of a pharmaceutical composition
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
EP1417958A1 (de) 2002-11-08 2004-05-12 Pari GmbH Feuchtgranulierungsverfahren
AU2002356646A1 (en) 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
DE112004001191B4 (de) 2003-07-02 2017-11-09 Corus Pharma Inc. Verfahren zur Herstellung des L-Lysin-Salzes von Aztreonam und Verfahren zur Bestimmung des Verunreinigungsgrads in einem amorphen Aztreonam Lysin-Salz
AR068514A1 (es) 2007-10-01 2009-11-18 Gilead Sciences Inc Aztreonam lisina inhalada para el tratamiento de deficits de salud relacionados con la calidad de vida (cvrs) de las enfermedades pulmonares

Also Published As

Publication number Publication date
CA2433280C (en) 2010-09-21
BE2011C029I2 (de) 2021-07-26
NL300492I2 (nl) 2017-11-02
US20170296517A1 (en) 2017-10-19
US20140037735A1 (en) 2014-02-06
CY2011012I2 (el) 2014-04-09
CA2708703A1 (en) 2002-07-04
CA2433280A1 (en) 2002-07-04
EP2301524A1 (de) 2011-03-30
CY1111571T1 (el) 2014-04-09
PT1353647E (pt) 2011-05-24
LU91851I9 (de) 2019-01-03
NO20101377L (no) 2003-08-26
PT2301524E (pt) 2013-07-10
US9533000B2 (en) 2017-01-03
IL156596A0 (en) 2004-01-04
CA2708703C (en) 2012-12-04
WO2002051356A2 (en) 2002-07-04
FR11C0030I2 (fr) 2012-03-16
ATE502623T1 (de) 2011-04-15
NO329643B1 (no) 2010-11-22
DK2301524T3 (da) 2013-07-15
IL221036A0 (en) 2012-08-30
EP2301524B1 (de) 2013-04-24
DE122011100043I1 (de) 2011-12-15
NO2011001I2 (no) 2013-05-27
NO20032946D0 (no) 2003-06-26
CY2011012I1 (el) 2014-04-09
US20080050439A1 (en) 2008-02-28
EP1353647A4 (de) 2007-05-09
JP4646489B2 (ja) 2011-03-09
EP1353647A2 (de) 2003-10-22
AU2002231244B2 (en) 2006-06-29
NO2011001I1 (no) 2011-02-07
BRPI0116757B8 (pt) 2021-05-25
ES2406405T3 (es) 2013-06-06
JP2004516302A (ja) 2004-06-03
US6660249B2 (en) 2003-12-09
FR11C0030I1 (de) 2011-09-23
US7208141B2 (en) 2007-04-24
ES2360692T3 (es) 2011-06-08
LU91851I2 (fr) 2011-10-03
US20050129623A1 (en) 2005-06-16
DK1353647T3 (da) 2011-06-14
BR0116757A (pt) 2003-11-04
US20120093890A1 (en) 2012-04-19
US20030055034A1 (en) 2003-03-20
NO20032946L (no) 2003-08-26
IL156596A (en) 2012-07-31
EP1353647B1 (de) 2011-03-23
WO2002051356A3 (en) 2002-10-31
BR0116757B1 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
DE60144291D1 (de) Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen
CY1114621T1 (el) Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2003097575A3 (en) Amino-functional chalcones
EP1057828A3 (de) Trovafloxacin enhaltende Suspensionen zur oralen Anwendung
WO2002100327A3 (en) Substituted 1-benzazepines and derivatives thereof
WO2001097791A3 (fr) Utilisation d'acides en c4-c10 pour la prévention des infections a bactéries a gram négatif
EP1435357A3 (de) Neues Verfahren zur Herstellung von Vinyl-Pyrrolidin Cephalosporin Derivaten
CY1114144T1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
AR040420A1 (es) Aztreonam inhalable para el tratamiento y la prevencion de infecciones bacterianas pulmonares
EE05090B1 (et) Tsklipostiinihend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,hendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
BR0317425A (pt) Sal de rabeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
BR0307468A (pt) Derivados tiadiazinona antimicrobianos úteis no tratamento de infecções bacterianas
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales
GR1003520B (el) Μεθοδος χρησης ενωσεων φλουοροκινολονης εναντια σε νοσοκομειακα αρνητικα κατα gramμ παθογενων βακτηριδιων
IL172768A0 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Legal Events

Date Code Title Description
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: ZUSAMMENSETZUNG ENTHALTEND AZTREONAM, NICHT IN EINER ZUSAMMENSETZUNG MIT ARGININ, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ VON AZTREONAM, DAS KEIN ARGININSALZ IST; REGISTRATION NO/DATE: EU/1/09/543/001 20090921

Spc suppl protection certif: 122011100043

Filing date: 20110822

Free format text: PRODUCT NAME: ZUSAMMENSETZUNG ENTHALTEND AZTREONAM, NICHT IN EINER ZUSAMMENSETZUNG MIT ARGININ, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ VON AZTREONAM, DAS KEIN ARGININSALZ IST; REGISTRATION NO/DATE: EU/1/09/543/001 20090921

Spc suppl protection certif: 122011100043

Filing date: 20110822

Expiry date: 20211221

Effective date: 20111025

Free format text: PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921

Spc suppl protection certif: 122011100043

Filing date: 20110822

Expiry date: 20211221

Effective date: 20111025